Akebia Therapeutics Reports 49% Revenue Growth in 2025, Eyes Vafseo Expansion
Event summary
- Akebia Therapeutics reported $227.3M in net product revenues for 2025, a 49% increase from 2024.
- Vafseo (vadadustat) patient access expanded to 290,000, with improved adherence rates at 91% in Q4 2025.
- Phase 2 trial for praliciguat in FSGS initiated, with AKB-097 rare kidney disease basket trial planned for 2H 2026.
- Auryxia revenues grew 19% YoY, but generic competition expected to impact 2026 performance.
- Cash position strengthened to $184.8M, sufficient for at least two years of operations.
The big picture
Akebia's strong 2025 financial performance underscores Vafseo's growing traction in the anemia treatment market for dialysis patients. The company's strategic focus on expanding patient access and advancing its rare kidney disease pipeline positions it to capitalize on unmet medical needs. However, the biopharmaceutical sector's competitive pressures, particularly from generics, will test Akebia's ability to maintain its growth trajectory.
What we're watching
- Commercial Momentum
- Whether Akebia can sustain Vafseo's revenue growth through expanded dialysis organization access and new patient starts.
- Pipeline Progress
- The pace at which praliciguat and AKB-097 advance through clinical trials, particularly in rare kidney disease indications.
- Competitive Dynamics
- How Akebia navigates generic competition for Auryxia while maintaining Vafseo's market position.
Related topics